Citius Oncology, Inc.
NASDAQ:CTORDrug Manufacturers - General
+$0.03 today
- Market cap
- $51.83M
- Beta
- 3.42
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$0.42
Volume 0.15M
Average 0.12M
CTOR Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Citius Oncology, Inc.NASDAQ: CTOR
Selling, General & Admin · Q2 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q2 FY2026 selling, general & admin of $27.15M rose 526.8% year over year, ahead of the +127.0% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 298.4% from the prior quarter. Over 3 fiscal years it compounded at +81.6% a year.
Context
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 1 analysts of $0 (-100.0%) for the fiscal year ending Sep 2026, a slowdown from the +9.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $27.15M+298.4% QoQ
- Last fiscal yearSep 2025
- $17.1M+9.3% YoY
- LTMMar 2026
- $41.61M+127.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +526.8% | -100.0% | -626.8 pp |
| 1 year | +9.3% | -100.0% | -109.3 pp |
| 3-year CAGR | +81.6% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 17.1M USD
- Year-over-year change
- +9.3%
- 3-year CAGR
- +81.6%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 17.1M | +9.3% |
| FY2024 | 2024-09-30 | 15.65M | +98.6% |
| FY2023 | 2023-09-30 | 7.88M | +175.8% |
| FY2022 | 2022-09-30 | 2.86M | — |
Selling, General & Admin vs competitors
How CTOR compares with its peers on the latest reported figures
- CTOR's LTM Mar 2026 selling, general & admin of $41.61M is the 5th highest of the 10 companies compared; the peer median is $36.54M.
- Its year-over-year change of +127.0% is the 2nd highest of 10, against a peer median of -0.9%.
- Selling, general & admin amounts to 741.5% of revenue for CTOR, versus a peer median of 366.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $269.6M | +128.9% | +60.2% | 796.2% | |
| LTM Mar 2026 | $51.12M | +107.0% | +36.0% | — | |
| LTM Mar 2026 | $50.4M | -0.9% | -15.8% | 47.1% | |
| LTM Mar 2026 | $42.34M | -49.3% | -18.0% | 670.4% | |
CTORCitius Oncology, Inc. | LTM Mar 2026 | $41.61M | +127.0% | +81.6% | 741.5% |
| LTM Mar 2026 | $36.54M | +18.5% | +18.5% | 63.3% | |
| LTM Mar 2026 | $35.34M | -27.5% | -17.7% | 3080.9% | |
| LTM Mar 2026 | $19.24M | -21.8% | -16.6% | 35.1% | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $12.2M | +39.9% | +47.3% | — |
| LTM Mar 2026 | $10.95M | -28.8% | +14.3% | — | |
| Peer median (excluding CTOR) | $36.54M | -0.9% | +14.3% | 366.9% | |
Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — |
| Research & Development | 6.86M | 4.24M | 4.93M | 6.42M |
| Selling, General & Admin | 2.86M | 7.88M | 15.65M | 17.1M |
| Operating Expenses | 9.71M | 12.12M | 20.57M | 23.52M |
| Depreciation & Amortization | 9.71M | 0 | 0 | 0 |
| EBITDA | 0 | (12.12M) | (20.57M) | (23.49M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (9.71M) | (12.12M) | (20.57M) | (23.52M) |
| Operating Margin | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 36.37K |
| Interest Expense | 0 | 0 | 0 | 218.03K |
| Other Income / Expenses | 0 | 0 | 0 | (181.66K) |
| Income Before Tax | (9.71M) | (12.12M) | (20.57M) | (23.7M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 1.15M | 576K | 576K | 1.06M |
| Net Income | (10.87M) | (12.7M) | (21.15M) | (24.76M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.08) | (0.19) | (0.30) | (0.34) |
| EPS (Diluted) | (0.08) | (0.19) | (0.30) | (0.34) |
| Weighted Avg Shares | 90.16M | 89.48M | 71.55M | 73.27M |
| Weighted Avg Shares (Diluted) | 90.16M | 89.48M | 71.55M | 73.27M |
Citius Oncology, Inc.
NASDAQ:CTOR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.